# Optimal Time Interval Between Mifepristone and Misoprostol Administration for Early Pregnancy Loss

> **NCT07506512** · PHASE3 · NOT_YET_RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 1000 (estimated)

## Conditions studied

- Early Pregnancy Loss

## Interventions

- **DRUG:** 200mg mifepristone and 800mg misoprostol

## Key facts

- **NCT ID:** NCT07506512
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2031-07
- **Final completion:** 2031-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07506512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07506512, "Optimal Time Interval Between Mifepristone and Misoprostol Administration for Early Pregnancy Loss". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07506512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*